MktsMarkets

Context Therapeutics Inc.
NASDAQ: CNTXKey statistics
CNTX News
Stories mentioning CNTX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | ||||||||
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (9,344) | (13,806) | (10,610) | (9,758) | (5,529) | (4,310) | (18,701) | (3,089) |
| Interest Income | 520.00 | 682.00 | 834.00 | 904.00 | 959.00 | 964.00 | 1,244 | 840.00 |
| Interest Expense | ||||||||
| Other Expense | 143.00 | 97.00 | 83.00 | 27.00 | (7.00) | 4.00 | (2.00) | (6.00) |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (8,681) | (13,026) | (9,693) | (8,828) | (4,577) | (3,342) | (17,460) | (2,255) |
| Earnings Per Share (Basic) | (0.09) | (0.14) | (0.10) | (0.09) | (0.05) | (0.06) | (0.22) | (0.04) |
| Earnings Per Share (Diluted) | (0.09) | (0.14) | (0.10) | (0.09) | (0.05) | (0.06) | (0.22) | (0.04) |
| Weighted Average Shares Outstanding (Basic) | 95,184 | 95,186 | 95,185 | 95,187 | 95,187 | 58,416 | 80,481 | 54,959 |
| Weighted Average Shares Outstanding (Diluted) | 95,184 | 95,186 | 95,185 | 95,187 | 95,187 | 58,416 | 80,481 | 54,959 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About CNTX
Context Therapeutics Inc. (NASDAQ: CNTX) is a stock listed on the Nasdaq Stock Market under the ticker symbol CNTX. It last traded at $0.2400 (Oct 23, 2026, 4:00 PM ET), up 1.6% on the day. That gives Context Therapeutics a market capitalisation of $22.0M.
Over the past 52 weeks CNTX has traded between $0.2200 and $3.62.
For the quarter ended Mar 31, 2026 it reported a net loss of $8.7M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$8.7M |
| Dec 31, 2025 | — | -$13.0M |
| Sep 30, 2025 | — | -$9.7M |
| Jun 30, 2025 | — | -$8.8M |
From Context Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…